Cite
HARVARD Citation
Massard, C. et al. (2017). Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. Annals of oncology. pp. 90-95. [Online].